LLY News

Amphista Therapeutics announces three presentations at the American Association for Cancer Research Annual Meeting on its next-generation Targeted Glue™ degrader programs

Algernon to Open the First Brain Dedicated PET Scanning Clinic in the U.S. at the HCA Florida University Medical Office Building

Amphista Therapeutics announces three presentations at the American Association for Cancer Research Annual Meeting on its next-generation Targeted Glue™ degrader programs

ReflexMD GLP-1 Claims Evaluated: Safety Risks Assessed for Reflex MD Semaglutide Telemedicine Provider

Trim RX GLP-1 Weight Loss Medication Claims Evaluated: Investigating the TrimRX Treatment Options

Caliway Selected to Present Preclinical Data on CBL-514 in Combination with GLP-1R Therapy at ECO 2026

Kalohexis Emerges from Stealth to Advance First- and Best-in-Class Therapeutics Harnessing the Melanocortin System to Treat Obesity and Metabolic Diseases

Fauna Bio Announces Target Designation Milestone in Obesity Discovery Collaboration

Lilly's triple agonist, retatrutide, demonstrated significant reductions in A1C and weight in first Phase 3 trial for treatment of type 2 diabetes

Radioligand Therapeutics Market to More Than Double to $4.8 Billion by 2030 as Targeted Cancer Treatments Gain Regulatory Momentum